Table 1.
Human papillomavirus (HPV) type prevalence and risks for progression from viral infection to cervical intraepithelial neoplasia (CIN) 2–3 or invasive cervical cancer (ICC) in Japan
| HPV type | Normal cytology | CIN1 | CIN2–3 | ICC | Prevalence ratios | Odds ratio‡ | ||||
|---|---|---|---|---|---|---|---|---|---|---|
| (n = 342) | (n = 281) | (n = 291) | (n = 131) | CIN2–3 + ICC: NL | CIN2–3 + ICC: NL | |||||
| n | % † | n | % | n | % | n | % | (95% CI) | (95% CI) | |
| Oncogenic types (HC2 types) | 222 | 64.9 | 188 | 66.9 | 231 | 79.4 | 110 | 84.0 | 1.24 (1.10–1.41) | 72.2 (47.9–113.7) |
| HPV16/18/31/33/35/52/58 | 129 | 37.7 | 117 | 41.6 | 200 | 68.7 | 106 | 80.9 | 1.92 (1.58–2.34) | 111.5 (72.7–178.1) |
| HPV39/45/51/56/59/68 | 93 | 27.2 | 71 | 25.3 | 31 | 10.7 | 4 | 3.1 | 0.31 (0.19–0.50) | 17.7 (10.2–31.1) |
| HPV16 | 40 | 11.7 | 27 | 9.6 | 70 | 24.1 | 53 | 40.5 | 2.49 (1.61–3.87) | 144.5 (86.3–251.3) |
| HPV18 | 19 | 5.6 | 19 | 6.8 | 20 | 6.9 | 32 | 24.4 | 2.22 (1.12–4.41) | 128.6 (68.0–254.6) |
| HPV31 | 4 | 1.2 | 6 | 2.1 | 13 | 4.5 | 2 | 1.5 | 3.04 (0.73–12.7) | 176.2 (59.3–653.3) |
| HPV33 | 8 | 2.3 | 7 | 2.5 | 10 | 3.4 | 4 | 3.1 | 1.42 (0.44–4.61) | 82.2 (32.4–223.3) |
| HPV35 | 2 | 0.6 | 7 | 2.5 | 5 | 1.7 | 0 | 0 | 2.02 (0.24–17.1) | 117.5 (24.1–848.2) |
| HPV39 | 11 | 3.2 | 2 | 0.7 | 1 | 0.3 | 2 | 1.5 | 0.22 (0.01–1.15) | 12.8 (2.8–44.1) |
| HPV45 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | NA | NA |
| HPV51 | 40 | 11.7 | 35 | 12.5 | 19 | 6.5 | 1 | 0.8 | 0.41 (0.20–0.83) | 23.5 (12.0–45.9) |
| HPV52 | 32 | 9.4 | 32 | 11.4 | 51 | 17.5 | 11 | 8.4 | 1.57 (0.90–2.74) | 91.1 (51.7–166.0) |
| HPV56 | 20 | 5.8 | 25 | 8.9 | 8 | 3 | 0 | 0 | 0.32 (0.12–0.97) | 18.8 (7.2–45.6) |
| HPV58 | 24 | 7.0 | 19 | 6.8 | 31 | 10.7 | 4 | 3.1 | 1.18 (0.59–2.38) | 68.5 (36.1–133.9) |
| HPV59 | 15 | 4.4 | 4 | 1.4 | 3 | 1.0 | 0 | 0 | 0.16 (0.03–0.77) | 9.4 (2.1–30.8) |
| HPV68 | 7 | 2.0 | 5 | 1.8 | 0 | 0 | 1 | 0.8 | 0.12 (0.01–1.34) | NA |
| Non‐oncogenic (non‐HC2 types) | 55 | 16.1 | 25 | 8.9 | 11 | 3.8 | 2 | 1.5 | 0.09 (0.03–0.43) | 11.1 (5.3–22.6) |
| HPV6/11 | 11 | 3.2 | 6 | 2.1 | 0 | 0 | 0 | 0 | NA | NA |
| HPV53 | 16 | 4.7 | 13 | 4.6 | 7 | 2.4 | 2 | 1.5 | 0.45 (0.15–1.38) | 26.4 (10.3–64.8) |
| HPV54 | 4 | 1.2 | 0 | 0 | 0 | 0 | 0 | 0 | NA | NA |
| HPV61 | 11 | 3.2 | 3 | 1.1 | 0 | 0 | 0 | 0 | NA | NA |
| HPV66 | 5 | 1.5 | 3 | 1.1 | 0 | 0 | 0 | 0 | NA | NA |
| HPV70 | 5 | 1.5 | 0 | 0 | 1 | 0.3 | 0 | 0 | 0.16 (0.01–2.12) | 9.4 (0.5–61.2) |
| HPV82 | 3 | 0.9 | 0 | 0 | 3 | 1.0 | 0 | 0 | 0.81 (0.10–9.00) | 47.0 (8.4–265.1) |
| Undetermined § | 24 | 7.0 | 16 | 5.7 | 16 | 5.5 | 6 | 4.6 | 0.65 (0.21–2.02) | 43.1 (21.4–87.7) |
| Multiple | 41 | 12.0 | 52 | 18.5 | 33 | 11.3 | 13 | 9.9 | 0.83 (0.37–1.81) | 52.7 (29.9–95.4) |
*
Percentage among HPV‐positive women.
† For estimation of odds ratios and 95% confidence intervals (CI), patients with cervical cancer who were negative for HPV (n = 9) and control individuals who were negative for HPV (n = 1175) were used as reference categories.
§
Undetermined HPV types denote that HPV types were unclassified or not determined due to weak reactions. NA, not available; NL, nonual cytology.